Cargando…
Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials
In 2014, our research network was involved in the evaluation of favipiravir, an anti‐influenza polymerase inhibitor, against Ebola virus. In this review, we discuss how mathematical modeling was used, first to propose a relevant dosing regimen in humans, and then to optimize its antiviral efficacy i...
Autores principales: | Madelain, Vincent, Mentré, France, Baize, Sylvain, Anglaret, Xavier, Laouénan, Cédric, Oestereich, Lisa, Nguyen, Thi Huyen Tram, Malvy, Denis, Piorkowski, Géraldine, Graw, Frederik, Günther, Stephan, Raoul, Hervé, de Lamballerie, Xavier, Guedj, Jérémie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239338/ https://www.ncbi.nlm.nih.gov/pubmed/32198838 http://dx.doi.org/10.1002/psp4.12510 |
Ejemplares similares
-
Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted
por: Nguyen, Thi Huyen Tram, et al.
Publicado: (2017) -
Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques
por: Guedj, Jérémie, et al.
Publicado: (2018) -
Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates
por: Reynard, Stéphanie, et al.
Publicado: (2021) -
Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies
por: Madelain, Vincent, et al.
Publicado: (2018) -
The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers
por: Malvy, Denis, et al.
Publicado: (2020)